Stock Markets May 5, 2026 01:33 PM

Trump Presses FDA Commissioner Over Pace of Flavored Vape Approvals, Report Says

President sought advisers' views on Marty Makary's stance as only tobacco and menthol vape products hold FDA authorization

By Maya Rios
Trump Presses FDA Commissioner Over Pace of Flavored Vape Approvals, Report Says

President Donald Trump has criticized FDA Commissioner Marty Makary for what he sees as slow action on approving flavored vaping and nicotine products, according to people cited by the Wall Street Journal. Trump discussed the issue and Makary's role with advisers in multiple White House conversations, with aides telling the president the commissioner has impeded his pledge to "save" vaping made in September 2024. Regulators have so far authorized only 41 vape products, all tobacco or menthol flavors, and the FDA has maintained strict evidence requirements for flavors that may appeal strongly to youth.

Key Points

  • President Trump criticized FDA Commissioner Marty Makary for the pace of approvals for flavored vaping and nicotine products.
  • Advisers told Trump Makary has prevented the administration from fulfilling a pledge to "save" vaping made in September 2024 on Truth Social.
  • Regulators have authorized only 41 vape products so far, all featuring tobacco or menthol flavors; the FDA requires strong evidence of benefit to smokers for flavors that appeal to youth.

President Donald Trump expressed dissatisfaction with Food and Drug Administration Commissioner Marty Makary over the weekend, criticizing him for not moving quickly enough to approve flavored vaping and nicotine products, people familiar with the matter told the Wall Street Journal.

According to the report, Trump held multiple calls and White House conversations with advisers to discuss Makary and the importance of flavored vaping to young "Make America Great Again" voters. Advisers portrayed the commissioner as a problem for the administration and said Makary has stood in the way of the president delivering on a campaign pledge to "save" vaping, a promise Trump made in September 2024 on Truth Social.

U.S. regulators have not granted authorizations for flavored vape products to date. The FDA has said it will require strong evidence that any flavors likely to appeal to youth - such as fruit or candy varieties - provide benefits to adult smokers. As of this week, only 41 vape products are authorized for sale, and those authorized products feature tobacco or menthol flavors.

The Wall Street Journal's sources reported that Trump and Makary discussed whether the commissioner might shift his position on flavored vapes. No formal decision has been announced, though some sources cited by the report suggested Makary was considering a more open approach to flavor approvals.

The conversations reported over the weekend underscore a clash between political priorities and agency regulatory standards. The FDA's stated requirement for evidence demonstrating benefit to smokers is a continuing benchmark for any flavor authorizations, particularly for flavors the agency assesses as having strong youth appeal.


Context and implications

The matter centers on whether the FDA will authorize additional vape flavors beyond tobacco and menthol, balancing the administration's political commitments with the agency's evidence-based standards. According to the report, advisers advised the president that Makary's actions have delayed the fulfillment of the administration's pledge on vaping.

No timetable or official action was reported, and the status quo remains that 41 products are authorized and those products are limited to tobacco or menthol flavors.

Risks

  • Regulatory uncertainty for the vaping and nicotine-products sector, given that flavored products remain unauthorized and the FDA maintains strict evidence thresholds.
  • Political pressure on the FDA could create uncertainty for public-health regulatory processes and for companies in the vaping and consumer nicotine markets.
  • Potential public-health concerns tied to flavors that appeal to youth, which the FDA has identified as requiring rigorous evidence of benefit to adult smokers before approval.

More from Stock Markets

Criteo Extends ChatGPT Ad Integration as Shares Tick Higher May 5, 2026 Short Interest Climbs as Nike Struggles to Rebuild Momentum Under CEO Hill May 5, 2026 Microchip Technology Climbs Toward Yearly High as Analysts Lift Targets Ahead of Q4 Results May 5, 2026 Marvell Rallies After UBS Boosts Price Target to $195, Citing AI Data Center Strength May 5, 2026 Apimeds Pharma Stock Surges After Settlement Clears Path for Merger and PIPE May 5, 2026